Radiation boost may extend life in advanced kidney cancer

NCT ID NCT06583070

Recruiting now Disease control Sponsor: Peking University First Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether adding a precise type of radiation (SABR) to standard drug therapy (targeted therapy plus immunotherapy) can help people with recurrent or metastatic kidney cancer live longer without their disease getting worse. About 300 participants will be enrolled, and researchers will compare outcomes between those who get radiation plus drugs versus drugs alone. The goal is to see if this combination improves local tumor control and overall survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC RENAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

kidney cancer renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC RENAL CANCER RADIATION THERAPY RECURRENT RENAL CELL CANCER

Contacts and locations

Locations

Peking University First Hospital
RECRUITING

Beijing, Beijing Municipality, 100034, China
Peking University Third Hospital
RECRUITING

Beijing, Beijing Municipality, 100091, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.